Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P48382

UPID:
RFX5_HUMAN

ALTERNATIVE NAMES:
Regulatory factor X 5

ALTERNATIVE UPACC:
P48382; B7Z848; D3DV19; E9PFU4; Q5VWC3

BACKGROUND:
The DNA-binding protein RFX5, alternatively named Regulatory factor X 5, is essential for the proper functioning of the immune system. It is involved in activating transcription from class II MHC promoters and in the recognition of X-boxes, facilitating the cooperative binding of RFX and NF-Y to MHC-II promoters.

THERAPEUTIC SIGNIFICANCE:
Linked to the development of Bare lymphocyte syndrome 2, a condition marked by severe immunodeficiency and heightened infection risk, RFX5's role is critical. Exploring the functions of RFX5 offers a promising pathway to developing new treatments for immune system diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.